Martine Zimmermann
Director/Board Member en INVENTIVA .
Fortuna: 167 034 $ al 31/03/2024
Cargos activos de Martine Zimmermann
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| INVENTIVA | Director/Board Member | 16/04/2021 | - |
| Independent Dir/Board Member | 16/04/2021 | - | |
| LIGAND PHARMACEUTICALS INCORPORATED | Director/Board Member | 26/09/2023 | - |
| Independent Dir/Board Member | 26/09/2023 | - | |
| Ipsen Biopharmaceuticals, Inc. | General Counsel | - | - |
Historial de carrera de Martine Zimmermann
Antiguos cargos conocidos de Martine Zimmermann.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | General Counsel | 01/06/2016 | 01/02/2023 |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Director/Board Member | 01/03/2019 | 01/01/2021 |
Formación de Martine Zimmermann.
| University of Strasbourg | Doctorate Degree |
| Louis Pasteur University | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 5 |
| Francia | 4 |
Operativa
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| General Counsel | 2 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| INVENTIVA | Health Technology |
| Empresas privadas | 3 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
| Ipsen Biopharmaceuticals, Inc. | |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Martine Zimmermann
- Experiencia
